Marker Therapeutics MRKR
NASDAQ MRKR
$1.05 -0.02 (-1.87%)
At close: Oct 1, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Current Deferred Revenue (2021 - 2025)

Updated

Marker Therapeutics (MRKR) posted Current Deferred Revenue of $974,799 for Q4 2025, down 30.4% from the prior quarter.

Analysis

Marker Therapeutics (MRKR) Current Deferred Revenue (2021 - 2025) Analysis & Trends

Since Q4 2021, Marker Therapeutics has reported Current Deferred Revenue for 6 quarters.

  • Annual Current Deferred Revenue shows a four-year compound annual growth rate of -4.0% (FY2021 to FY2025).
  • In prior years, Marker Therapeutics' Current Deferred Revenue was $1.15 million in FY2021.
  • The Q4 2025 figure stands as the lowest quarterly Current Deferred Revenue since Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Marker Therapeutics 17.87 Mn -42.04 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 974,799.00
Sep 30, 2025 1.40 Mn
Jun 30, 2025 1.40 Mn
Sep 30, 2023 107,530.00
Mar 31, 2022 181,864.00
Dec 31, 2021 1.15 Mn
API Access

Marker Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=MRKR&period=max&api_key=YOUR_API_KEY